According to available data from subgroup analyses, immunotherapy as single agent seem to work in elderly similarly to younger patients, with no excess of toxicities. In contrast, the real impact - and not least the safety - of an immune-chemo combination use in elderly population was still unclear. Awaiting data from dedicated clinical trials, this review will discuss available results from randomized phase III clinical trials comparing immune-chemo combinations to chemotherapy alone, focusing on elderly subgroup enrolled.
Keyphrases
- phase iii
- clinical trial
- open label
- middle aged
- advanced non small cell lung cancer
- double blind
- phase ii
- community dwelling
- photodynamic therapy
- placebo controlled
- locally advanced
- electronic health record
- combination therapy
- epidermal growth factor receptor
- magnetic resonance
- study protocol
- big data
- rectal cancer
- magnetic resonance imaging
- drug delivery